billS1782Event Wednesday, June 17, 2026Analyzed

Charlotte Woodward Organ Transplant Discrimination Prevention Act

Neutral

Summary

S.1782, the Charlotte Woodward Organ Transplant Discrimination Prevention Act, was reported favorably out of the Senate HELP Committee on June 17, 2026. The bill prohibits discrimination based on disability in organ transplant eligibility, requiring covered healthcare entities to make reasonable modifications. No direct funding is authorized; the impact is regulatory compliance for transplant hospitals and providers.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.1782 is a regulatory compliance bill, not a funding bill
  • 2.Transplant hospitals and providers must adjust eligibility protocols
  • 3.Bipartisan support increases likelihood of passage

Market Implications

The bill is neutral for healthcare sector stocks in the near term. No direct financial impact is authorized. Investors should monitor floor action and potential amendments. The regulatory burden is modest and unlikely to materially affect earnings for large-cap healthcare companies like UNH or JNJ.

Full Analysis

  1. What happened: On June 17, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered S.1782 to be reported favorably with an amendment. The bill, introduced by Sen. Moody (R-FL) with 21 cosponsors, now awaits floor action. It is a companion to H.R.1520 in the House. 2) Money trail: The bill does not authorize or appropriate any funding. It imposes a regulatory mandate on covered entities (hospitals, transplant centers, health care providers) to not discriminate on the basis of disability in organ transplant eligibility. 3) Structural winners and losers: The primary impact is on transplant hospitals and healthcare providers. HCA, UNH, and JNJ are affected as they operate or supply transplant services. The bill removes barriers for disabled individuals, potentially increasing the pool of eligible transplant candidates, which could drive modest volume growth for transplant-related drugs and services. 4) No real market data provided; analysis is based on legislative structure. 5) Timeline: The bill must pass the full Senate, then the House (companion H.R.1520 is also in committee), then be signed by the President. Given the bipartisan sponsorship (21 cosponsors including both parties), passage is plausible but not guaranteed.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$HCA● Neutral
0

What the bill does

Prohibition on discrimination based on disability in organ transplant eligibility criteria

Who must act

Covered entities including licensed health care providers, hospitals, nursing facilities, laboratories, and transplant hospitals

What happens

Mandates that transplant hospitals and providers cannot deny or delay organ transplants based on disability status; requires reasonable modifications to policies and practices for qualified individuals with disabilities

Stock impact

HCA operates a large network of hospitals and transplant centers; the bill imposes compliance and operational costs to adjust transplant eligibility protocols, but may increase patient volume for transplant services as barriers are removed

Key Legislators

Sen. Moody, Ashley [R-FL]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →